CD226 and systemic sclerosis: DNAM-1 is also overexpressed in the skin of patients with SSc (39) and upregulattion of DNAM-1 in CD8+ T cells is associated with disease severity, suggesting this factor to be a potential therapeutic target in SSc (42).